Jaguar8 commented on a stock · Oct 16, 2024 20:33

NEWS

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

Jaguar Health (NASDAQ:JAGX) has launched Gelclair, an FDA-approved oral mucositis prescription product, in the U.S. This marks Jaguar's third commercialized prescription productand initiates its commercial footprint in cancer supportive care. Gelclair is a gel that adheres to the mouth's mucosal surface, providing rapid and long-lasting pain relief without stinging or numbing.
Oral mucositis, affecting up to 90% of head and neck cancer patients treated with chemotherapy and radiotherapy, is a significant adverse event in oncology. It can lead to treatment interruptions and hospitalization. Jaguar's launch strategy includes a dedicated team of representatives and plans to exhibit at key oncology conferences.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more